BMS-986360 + docetaxel

**BMS-986360 + docetaxel** is an investigational combination therapy for advanced solid tumors, composed of BMS-986360 and docetaxel. BMS-986360 (also known as CC-90001) is a small molecule inhibitor targeting c-Jun N-terminal kinase (JNK), a signaling pathway implicated in tumor cell proliferation, immune regulation within the tumor microenvironment, and fibrotic diseases[4][5][6]. Docetaxel is a well-established cytotoxic chemotherapy agent (a taxane) that disrupts microtubule dynamics, leading to cell cycle arrest and apoptosis. The combination is under clinical evaluation for its safety and potential antitumor efficacy, aiming to leverage BMS-986360’s immune-modulatory and anti-proliferative effects with the cytotoxic action of docetaxel, primarily in advanced or refractory solid malignancies such as lung cancer, breast cancer, and others[2][5][7].